OXB Pivots to Profitability with 30% Revenue Growth in FY 2025
Event summary
- OXB expects FY 2025 revenues of £166-169 million, up ~30% YoY and nearly 90% since FY 2023.
- Operating EBITDA profitability achieved in mid-to-high single-digit £ millions, including a non-recurring gain from the Durham acquisition.
- Contracted client orders grew 20% to £224 million, with revenue backlog increasing to £204 million.
- OXB secured £60 million in equity and a $125 million loan facility for capacity expansion.
The big picture
OXB’s shift to profitability underscores the growing demand for viral vector services in cell and gene therapy. The company’s strategic acquisitions and financing moves position it to capitalize on industry momentum, though execution risks remain as it scales operations. With a strong backlog of client orders, OXB is poised to outperform broader market growth rates in the near term.
What we're watching
- Revenue Growth Sustainability
- Whether OXB can maintain 25-30% YoY revenue growth in 2027 and 2028 amid broader market conditions.
- Margin Expansion
- The pace at which OXB achieves its target of 20%+ EBITDA margins by FY 2027 as capacity is utilized.
- Strategic Investments
- How OXB's planned capacity expansions will impact operational efficiency and client demand.
Our editorial coverage:
Related topics